CuraGen Corporation – ‘8-K’ for 9/18/02

On:  Wednesday, 9/18/02, at 5:15pm ET   ·   For:  9/18/02   ·   Accession #:  927016-2-4600   ·   File #:  0-23223

in

this entire Filing. an “Entity” Search.

Show

Documents searched

and

each “hit”. the 1st “hit”.

↓↑Hints

Current Report   —   Form 8-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                         3     10K 
 2: EX-99.1     Press Release                                          2     13K 

8-K   —   Current Report
Document Table of Contents

8-K
1st Page of 3
TOC
↑Top
Previous
Next
↓Bottom
Just 1st
 
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

--------------

FORM 8-K

CURRENT REPORT

 Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

--------------

Date of Report (Date of earliest event reported): September 18, 2002            

 CuraGen Corporation
(Exact name of registrant as specified in its charter)

Delaware                         0-23223                   06-1331400   
--------------------------------------------------------------------------------
(State or other                    (Commission                (IRS Employer     
jurisdiction of                    File Number)             Identification No.) 
incorporation)                                                                  

555 Long Wharf Drive, 11th Floor
New Haven, Connecticut 06511
--------------------------------------------------------------------------------
 (Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (203) 401-3330              

--------------------------------------------------------------------------------

8-K
2nd Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 2nd
Item 5. Other Events and Regulation FD Disclosure.                              

On September 18, 2002, the Registrant issued a press release announcing that    
scientists of the Registrant, in collaboration with Bayer AG's toxicologists,   
have developed an innovative technology capable of predicting a drug compound's 
potential for toxicity. The Predictive Toxicogenomics Screen(TM) evaluates drug 
compound toxicities using very small quantities of compounds that are available 
immediately after high-throughput drug screening and well in advance of the     
expensive drug scale-up required for mammalian safety experiments. Utilizing the
Predictive Toxicogenomics Screen early in the drug development process,         
scientists are able to rank-order compounds by their predicted safety profiles. 
Registrant and Bayer scientists have completed evaluating more than 150         
preclinical drug compounds with the Predictive Toxicogenomics Screen and have   
ranked these compounds according to their potential for toxicity. Based upon the
success achieved through the initial application of this predictive technology, 
Registrant and Bayer scientists are now applying the technology to conduct drug 
toxicity evaluations on Bayer's small molecule research pipeline. The Registrant
received a milestone payment of $2.9 million from Bayer for successfully        
developing this technology and industrializing it into a high-throughput format.
A copy of the press release is attached to this Current Report on Form 8-K as   
Exhibit 99.1.                                                                   

Item 7.   Financial Statements and Exhibits.                                    

(c) The following exhibits are filed with this report:                          

Exhibit Number                      Description                                 
--------------                      -----------                                 

 99.1              Press release of Registrant dated September 18, 2002.

2 

8-K
Last Page of 3
TOC
1st
Previous
Next
↓Bottom
Just 3rd
SIGNATURES

  Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the        
undersigned hereunto duly authorized.                                           

             CURAGEN CORPORATION
      (Registrant)

Date: September 18, 2002             By:  /s/ David M. Wurzer                   
                                         -------------------------------------
                           Name:   David M. Wurzer
                                        Title:  Executive Vice President and
                                           Chief Financial Officer

3 

Dates Referenced Herein

				Referenced-On Page
This ‘8-K’ Filing		Date		First		Last			Other Filings
Filed on / For Period End:		9/18/02		1		3			None on these Dates
									List all Filings